285 related articles for article (PubMed ID: 28176023)
1. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer.
Aoyama T; Sato T; Maezawa Y; Kano K; Hayashi T; Yamada T; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
Int J Clin Oncol; 2017 Jun; 22(3):476-483. PubMed ID: 28176023
[TBL] [Abstract][Full Text] [Related]
2. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
[TBL] [Abstract][Full Text] [Related]
3. [Effect of enteral nutrition enriched with eicosapentaenoic acid on body weight loss and compliance with S-1 adjuvant chemotherapy after gastric cancer surgery].
Aoyama T; Hayashi T; Fujikawa H; Ogata T; Cho H; Wada H; Kitani Y; Yukawa N; Oshima T; Rino Y; Ozawa Y; Masuda M; Yoshikawa T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2289-91. PubMed ID: 24394088
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
[TBL] [Abstract][Full Text] [Related]
6. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
[TBL] [Abstract][Full Text] [Related]
7. Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer.
Aoyama T; Kawabe T; Fujikawa H; Hayashi T; Yamada T; Tsuchida K; Yukawa N; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
Ann Surg Oncol; 2015 Aug; 22(8):2560-6. PubMed ID: 25515199
[TBL] [Abstract][Full Text] [Related]
8. The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy.
Kano K; Aoyama T; Maezawa Y; Nakajima T; Ikeda K; Yamada T; Sato T; Oshima T; Rino Y; Masuda M; Ogata T; Cho H; Yoshikawa T
Int J Clin Oncol; 2017 Oct; 22(5):887-896. PubMed ID: 28456896
[TBL] [Abstract][Full Text] [Related]
9. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of body weight loss in gastrectomy patients who underwent only surgery and those who underwent surgery followed up with S-1 adjuvant chemotherapy].
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Ogata T; Cho H; Yukawa N; Oshima T; Rino Y; Ozawa Y; Kitani Y; Wada H; Masuda M; Tsuburaya A
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1794-6. PubMed ID: 23267889
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
12. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study.
Oh SE; An JY; Choi MG; Lee JH; Sohn TS; Bae JM
Technol Cancer Res Treat; 2021; 20():15330338211039679. PubMed ID: 34605706
[No Abstract] [Full Text] [Related]
14. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
15. Impact of Body Weight Loss on Recurrence After Curative Gastrectomy for Gastric Cancer.
Kubo H; Komatsu S; Ichikawa D; Kawaguchi T; Kosuga T; Okamoto K; Konishi H; Shiozaki A; Fujiwara H; Otsuji E
Anticancer Res; 2016 Feb; 36(2):807-13. PubMed ID: 26851044
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
17. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.
Okuyama T; Korenaga D; Edagawa A; Itoh S; Oki E; Kawanaka H; Ikeda Y; Kakeji Y; Tateishi M; Tsujitani S; Takenaka K; Maehara Y
Surg Today; 2012 Aug; 42(8):734-40. PubMed ID: 22278622
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience.
Yen HH; Chen CN; Yeh CC; Lai IR
World J Surg Oncol; 2021 Apr; 19(1):124. PubMed ID: 33865416
[TBL] [Abstract][Full Text] [Related]
19. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Ito S; Ohashi Y; Sasako M
BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
Tsuchida K; Kunisaki C; Watanabe T; Ono H; Oshima T; Fukushima T; Yoshikawa T; Rino Y; Imada T; Masuda M
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2239-41. PubMed ID: 25731482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
